Bausch Health Companies (NYSE: BHC) was a very healthy stock Wednesday. Analyst Chris Schott from JPMorgan Chase's J.P. Morgan pointed out in his note that a sum-of-the-parts calculation indicates to him that Bausch stock could be worth around $40 (although he's maintaining his $38 price target). The prognosticator is also maintaining his overweight (buy) recommendation on the stock.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting